Status and trends of legislative and regulatory regulation of off-label use of drugs: A review

被引:0
作者
Zakharochkina, Elena R. [1 ]
Ryazhenov, Vasily V. [1 ]
Smolyarchuk, Elena A. [1 ]
Kudlay, Dmitry A. [1 ]
Bekhorashvili, Nana Yu [1 ]
Zaveryachev, Stanislav A. [1 ]
Sologova, Susanna S. [1 ]
机构
[1] Sechenov Univ, Sechenov Moscow State Med Univ 1, Moscow, Russia
关键词
medicinal products; medicinal products for human use; extemporaneous medicinal products; off-label use; se outside the Summary of Product Characteristics; coronavirus infection; manufacture of medicinal products; common market of medicinal products of the Eurasian Economic Union; English-language analogues of keywords and phrases;
D O I
10.26442/00403660.2024.04.202692
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The off-label use of drugs is a common practice worldwide. The legal basis for off-label medical use varies from country to country. Regulatory control of the pharmaceutical market in the off-label preventive and therapeutic practice at the international and national levels has become a breakthrough with the emergence of the coronavirus pandemic. The prospects for off-label use in the context of innovations in the legislation of public health in the Russian Federation are crucial. Professionally significant aspects of the use of medicinal products outside the Summary of Product Characteristics and the off-label use have been introduced by supranational regulatory authorities for the common market of medicinal products of the Eurasian Economic Union. Special attention should be paid to the regulatory control of the use of extemporaneous medicines as part of improving the government regulation of drug compounding in pharmacies. The active development of pharmacy activities in drug compounding within the framework of improving regulatory practice determines the relevance of actual off-label prescriptions and the use of extemporaneous formulations. Aim - to perform a systematic analysis of national, transnational legislative and regulatory documents regulating off-label use of medicinal products, determine the main conceptual components of the current regulatory pool and directions for future development in this area. Systematic analysis of the national legislative and regulatory pool of documents and the regulatory framework of the common market of medicinal products of the Eurasian Economic Union on the regulation of various aspects of the off-label use of medicinal products. Study of the components and identification of the main trends in the regulatory practice of prescriptions outside the Summary of Product Characteristics and the off-label use. An analytical search was carried out in the reference legal systems "ConsultantPlus" and "Garant" on the official websites of the Ministry of Health of Russia, the Eurasian Economic Union, the RusMed information resource of the National Library resource of Russia in medicine and pharmacy "Central Scientific Medical Library" was used. A logical generalization of the results on the current state of the legal framework and the development of conceptual proposals on the key directions of the prospective development of regulation, control, and supervisory activities of the pharmaceutical off-label use of medicinal products was made
引用
收藏
页码:396 / 406
页数:11
相关论文
共 44 条
[1]   New role of extemporaneous manufacturing in regulating drug products access onto the market [J].
Alekhin, A. V. ;
Erivantseva, T. N. ;
Ryazhenov, V. V. ;
Lyskov, N. B. ;
Alekhina, N. A. ;
Kuznetsova, M. M. .
PHARMACY & PHARMACOLOGY-FARMATSIYA I FARMAKOLOGIYA, 2023, 11 (02) :161-172
[2]  
alta, O Pravilakh registratsii i ekspertizy lekarstvennykh sredstv dlia meditsinskogo primeneniia: Reshenie Soveta Evraziiskoi ekonomicheskoi komissii ot 03.11.2016 No 78 (red. ot 20.10.2023)
[3]   Randomized Study of Rivaroxaban vs Placebo on Disease Progression and Symptoms Resolution in High-Risk Adults With Mild Coronavirus Disease 2019 [J].
Ananworanich, Jintanat ;
Mogg, Robin ;
Dunne, Michael W. ;
Bassyouni, Mohamed ;
David, Consuela Vera ;
Gonzalez, Erika ;
Rogalski-Salter, Taryn ;
Shih, Heather ;
Silverman, Jared ;
Medema, Jeroen ;
Heaton, Penny .
CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) :E473-E481
[4]  
base.garant, Ob utverzhdenii pravil nadlezhashchei klinicheskoi praktiki: Prikaz Minzdrava Rossii ot 01.04.2016 No 200n (zareg. v Miniuste Rossii 23.08.2016 No 43357)
[5]   The Role of Pharmaceutical Compounding in Promoting Medication Adherence [J].
Carvalho, Maria ;
Almeida, Isabel F. .
PHARMACEUTICALS, 2022, 15 (09)
[6]  
Cmehova IE, 2021, Vestnik farmacii, V1, P48, DOI [10.52540/2074-9457.2021.1.48, DOI 10.52540/2074-9457.2021.1.48]
[7]  
consultant, Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Versiia 18 ot 26.10.2023 (utv. Minzdravom Rossii) (vmeste s "Rekomendatsiiami po opisaniiu dannykh RG i KT OGKTS", "Instruktsiei po provedeniiu diagnostiki COVID-19 s primeneniem metodov amplifikatsii nukleinovykh kislot","Instruktsiei po provedeniiu diagnostiki COVID-19 s primeneniem immunokhimicheskikh metodov", "Rekomendovannymi skhemami lecheniia v ambulatornykh usloviiakh", "Rekomendovannymi skhemam
[8]  
consultant, O vnesenii izmenenii v Pravila nadlezhashchei praktiki farmakonadzora Evraziiskogo ekonomicheskogo soiuza: Reshenie Soveta Evraziiskoi ekonomicheskoi komissii ot 19.05.2022 No 81
[9]  
consultant, Lekarstvennaia terapiia ostrykh respiratornykh virusnykh infektsii (ORVI) v ambulatornoi praktike v period epidemii COVID-19. Versiia 2 ot 16.04.2020 (utv. Minzdravom Rossii): vremennye metodicheskie rekomendatsii
[10]  
consultant, Ob osobennostiakh obrashcheniia lekarstvennykh preparatov dlia meditsinskogo primeneniia, kotorye prednaznacheny dlia primeneniia v usloviiakh ugrozy vozniknoveniia, vozniknoveniia i likvidatsii chrezvychainoi situatsii i dlia organizatsii okazaniia meditsinskoi pomoshchi litsam, postradavshim v rezultate chrezvychainykh situatsii, preduprezhdeniia chrezvychainykh situatsii, profilaktiki i lecheniia zabolevanii, predstavliaiushchikh opasnost' dlia okruzhaiushchikh, zabolevanii i por